90 related articles for article (PubMed ID: 33253894)
1. Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19).
Li X
Ann Hepatol; 2021; 22():100295. PubMed ID: 33253894
[No Abstract] [Full Text] [Related]
2. Reply to: Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19).
López-Mendez I; Castro-Narro G
Ann Hepatol; 2021; 22():100326. PubMed ID: 33582320
[No Abstract] [Full Text] [Related]
3. MAFLD in COVID-19 patients: an insidious enemy.
Dongiovanni P; Meroni M; Longo M; Fracanzani AL
Expert Rev Gastroenterol Hepatol; 2020 Oct; 14(10):867-872. PubMed ID: 32705906
[TBL] [Abstract][Full Text] [Related]
4. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19.
Campos-Murguía A; Román-Calleja BM; González-Regueiro JA; Hurtado-Díaz-de-León I; Solís-Ortega AA; Flores-García NC; García-Juárez I; Ruiz-Margáin A; Macías-Rodríguez RU
World J Gastroenterol; 2021 Sep; 27(33):5502-5519. PubMed ID: 34588748
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data.
Díaz LA; Idalsoaga F; Cannistra M; Candia R; Cabrera D; Barrera F; Soza A; Graham R; Riquelme A; Arrese M; Leise MD; Arab JP
World J Gastroenterol; 2020 Dec; 26(48):7693-7706. PubMed ID: 33505145
[TBL] [Abstract][Full Text] [Related]
6. The Heightened Risk of Fatty Liver Disorders in the Time of COVID-19.
Stanfield D; Lucey MR
Mayo Clin Proc; 2020 Dec; 95(12):2580-2581. PubMed ID: 33276827
[No Abstract] [Full Text] [Related]
7. ACE2: from protection of liver disease to propagation of COVID-19.
Warner FJ; Rajapaksha H; Shackel N; Herath CB
Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 infection in patients with a normal or abnormal liver.
Cabibbo G; Rizzo GEM; Stornello C; Craxì A
J Viral Hepat; 2021 Jan; 28(1):4-11. PubMed ID: 33190321
[TBL] [Abstract][Full Text] [Related]
9. Direct or Collateral Liver Damage in SARS-CoV-2-Infected Patients.
Lizardo-Thiebaud MJ; Cervantes-Alvarez E; Limon-de la Rosa N; Tejeda-Dominguez F; Palacios-Jimenez M; Méndez-Guerrero O; Delaye-Martinez M; Rodriguez-Alvarez F; Romero-Morales B; Liu WH; Huang CA; Kershenobich D; Navarro-Alvarez N
Semin Liver Dis; 2020 Aug; 40(3):321-330. PubMed ID: 32886936
[TBL] [Abstract][Full Text] [Related]
10. Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019.
Gao F; Zheng KI; Yan HD; Sun QF; Pan KH; Wang TY; Chen YP; Targher G; Byrne CD; George J; Zheng MH
Front Endocrinol (Lausanne); 2021; 12():604100. PubMed ID: 33763027
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.
Wang Y; Liu S; Liu H; Li W; Lin F; Jiang L; Li X; Xu P; Zhang L; Zhao L; Cao Y; Kang J; Yang J; Li L; Liu X; Li Y; Nie R; Mu J; Lu F; Zhao S; Lu J; Zhao J
J Hepatol; 2020 Oct; 73(4):807-816. PubMed ID: 32437830
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection?
Singh MK; Mobeen A; Chandra A; Joshi S; Ramachandran S
Comput Biol Med; 2021 Mar; 130():104219. PubMed ID: 33486379
[TBL] [Abstract][Full Text] [Related]
13. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.
Targher G; Mantovani A; Byrne CD; Wang XB; Yan HD; Sun QF; Pan KH; Zheng KI; Chen YP; Eslam M; George J; Zheng MH
Gut; 2020 Aug; 69(8):1545-1547. PubMed ID: 32414813
[No Abstract] [Full Text] [Related]
14. Association of Maternal Perinatal SARS-CoV-2 Infection With Neonatal Outcomes During the COVID-19 Pandemic in Massachusetts.
Angelidou A; Sullivan K; Melvin PR; Shui JE; Goldfarb IT; Bartolome R; Chaudhary N; Vaidya R; Culic I; Singh R; Yanni D; Patrizi S; Hudak ML; Parker MG; Belfort MB
JAMA Netw Open; 2021 Apr; 4(4):e217523. PubMed ID: 33890989
[TBL] [Abstract][Full Text] [Related]
15. Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19.
Ibáñez-Samaniego L; Bighelli F; Usón C; Caravaca C; Fernández Carrillo C; Romero M; Barreales M; Perelló C; Madejón A; Marcos AC; Albillos A; Fernández I; García-Samaniego J; Calleja JL; Bañares R
J Infect Dis; 2020 Aug; 222(5):726-733. PubMed ID: 32563190
[TBL] [Abstract][Full Text] [Related]
16. Does MAFLD really increase the severity of COVID-19?
Fajar JK; Wibowo BP; Dewi GC; Rahmadi AP; Kusuma MT
Dig Liver Dis; 2021 Feb; 53(2):166-167. PubMed ID: 33208296
[No Abstract] [Full Text] [Related]
17. Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis.
Del Zompo F; De Siena M; Ianiro G; Gasbarrini A; Pompili M; Ponziani FR
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):13072-13088. PubMed ID: 33378061
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study.
Liu R; Zhao L; Cheng X; Han H; Li C; Li D; Liu A; Gao G; Zhou F; Liu F; Jiang Y; Zhu C; Xia Y
Liver Int; 2021 Apr; 41(4):720-730. PubMed ID: 33351265
[TBL] [Abstract][Full Text] [Related]
19. Reply to: "Liver fibrosis and adverse outcomes in COVID-19".
Ruiz-Margáin A; Campos-Murguía A; González-Regueiro JA; Román-Calleja BM; Delint DK; Macías-Rodríguez RU
Dig Liver Dis; 2021 Jul; 53(7):800. PubMed ID: 33947641
[No Abstract] [Full Text] [Related]
20. SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome.
Rosas-Salazar C; Kimura KS; Shilts MH; Strickland BA; Freeman MH; Wessinger BC; Gupta V; Brown HM; Rajagopala SV; Turner JH; Das SR
J Allergy Clin Immunol; 2021 Apr; 147(4):1226-1233.e2. PubMed ID: 33577896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
